News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

May 13, 2019

Summary Toggle aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update

Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host conference call and webcast today at 5:00pm EDT / 2:00 PDT SAN DIEGO , May 13, 2019 (GLOBE NEWSWIRE)
May 6, 2019

Summary Toggle aTyr Pharma to Announce First Quarter 2019 Results on May 13th

Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it
Apr 16, 2019

Summary Toggle aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology

Meeting to feature presentations on recent NRP-2-related discoveries by leading research experts in the field SAN DIEGO , April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Apr 11, 2019

Summary Toggle aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund

SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with The Federated
Apr 8, 2019

Summary Toggle aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference

ATYR1923 shown to modulate inflammatory and fibrotic processes in multiple interstitial lung disease (ILD) animal models SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based
Mar 25, 2019

Summary Toggle aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update

Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO , March 25, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the
Mar 21, 2019

Summary Toggle aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting

Abstract Describes Further Evidence that ATYR1923 Modulates Immune Cell Biology SAN DIEGO , March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today
Mar 18, 2019

Summary Toggle aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th

Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it
Mar 11, 2019

Summary Toggle aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring

Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline aTyr eligible to receive up to $17 million in potential option fees SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery
Mar 4, 2019

Summary Toggle aTyr Pharma Announces Participation at March Investor Conferences

SAN DIEGO , March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing clinical